NeuroPointDX, through its compound safety screening division Stemina Biomarker Discovery, has developed the leading metabolomics platform for identifying differences in metabolism in children with ASD and other neurological disorders.
NeuroPointDX has discovered differences in small molecules in the blood of children with ASD that allow earlier diagnosis and more precise treatment of children across the spectrum. NeuroPointDX is validating these markers and bringing its diagnostic test to market through its ongoing clinical study the Children’s Autism Metabolome Project (CAMP).
Company Details
- Founded
- -
- Address
- 504 S. Rosa Rd. Suite 150, Madison,wi 53719,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.neuropointdx.com
- HQ
- Madison, WI
- Competitors
- M&T Bank, btwb, Delair, Level Method.
Neuropointdx Questions
Neuropointdx's website is http://www.neuropointdx.com
Neuropointdx's LinkedIn profile is https://www.linkedin.com/company/neuropointdx
Neuropointdx's industry is
Biotechnology Research
Neuropointdx's categories are Biotechnology Research
Neuropointdx's founding year is 2016
